Program
infigratinib
Also written as “Infigratinib”, “BGJ398” and “infigratinib 0.128 mg/kg/day”.
Its studies are mostly in Achondroplasia · Mucopolysaccharidosis IV · Stomach Neoplasms · Cholangiocarcinoma · Urinary Bladder Neoplasms, led by 5 companies.
Drug pageInfigratinib: every studyMany companies study it; this page follows only the 17 they lead. All 30 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BridgeBioits history only | 83 open or running | phase 3since Dec 10, 2018 | May 12, 2014 | Jan 2027phase 3 · NCT06873035 |
| Novartisits history only | 50 open or running | phase 2since Oct 28, 2013 | Oct 27, 2009 | none ahead |
| LianBio | 20 open or running | phase 2since Jul 28, 2021 | Jul 28, 2021 | none ahead |
| Helsinn Healthcareits history only | 10 open or running | phase 2since Jan 12, 2022 | Jan 12, 2022 | none ahead |
| Pfizerits history only | 10 open or running | phase 2since Apr 28, 2014 | Apr 28, 2014 | none ahead |
Also a collaborator on its studies: Labcorp Corporation of America.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of LianBio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2021First study: phase 2 study in Stomach NeoplasmsFirst studyNCT05019794 · 80 enrolled · China
- Nov 29, 2023Phase 2 study in Stomach NeoplasmsNCT06206278 · 6 enrolled · China
TargetBeta
“Fibroblast growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| futibatinibrule | Otsuka | phase 3 | 10 |
Studies
All 2 LianBio leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06206278Stomach Neoplasms · China | 2 | Terminated | May 31, 2024 | 6 |
| NCT05019794Stomach Neoplasms · China | 2 | UNKNOWN | Dec 30, 2022 | 80 |
How it is read
Names in the registry
- “Infigratinib”, 7 entries
- “BGJ398”, 7 entries
- “infigratinib 0.128 mg/kg/day”, 1 entry
- “infigratinib 0.25 mg/kg/day”, 1 entry
- “Infigratinib 0.25 mg/kg/day”, 1 entry
Conditions, from the studies’ own filings
- Achondroplasia, 3 studies
- Mucopolysaccharidosis IV, 2 studies
- Stomach Neoplasms, 2 studies
- Cholangiocarcinoma, 2 studies
- Urinary Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.